Nasdaq · CIK 0001175151
CTSO Cytosorbents Corp
Insider trading from SEC Form 4. Last filing 27 d ago. Close $3.79 on Oct 9, 2026, +2% from the 52-week low and -80% from the high.
Cytosorbents Corp (CTSO) has 28 SEC Form 4 filings on file from 8 insiders, the latest filed on Sep 16, 2026. In the last 90 days insiders made 4 open-market buys worth $120k and 0 open-market sells worth $0, net +$120k.
8 open-market trades have been scored at CTSO. The newest: Vincent Capponi (President and COO) bought $13k of stock on Sep 14, 2026, filed Sep 16, 2026, scored 38 (weak). The largest of the 8 shown: Phillip P. Chan (Chief Executive Officer) bought $105k on Jun 12, 2026, scored 64 (notable). 3 insiders bought within 14 days of each other around Sep 14, 2026.
CTSO closed at $3.79 on Oct 9, 2026, 2% above its 52-week low and 80% below its 52-week high.
1 Form 144 notice of planned sales is on file, the latest filed Aug 19, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cytosorbents Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Vincent Capponi President and COO buy | $13k 2,073 shares | +5% | - | |
| 45Moderate | Phillip P. Chan Chief Executive Officer buy | $23k 3,774 shares | +4% | - | |
| 36Weak | Alan D. Sobel director buy | $15k 2,500 shares | +34% | - | |
| 51Moderate | Phillip P. Chan Chief Executive Officer buy | $70k 200,000 shares | +11% | - | |
| 47Moderate | Peter J Mariani Chief Financial Officer buy | $44k 100,000 shares | +19% | +11% from low-67% from high | |
| 64Notable | Phillip P. Chan Chief Executive Officer buy | $105k 261,469 shares | +18% | +3% from low-69% from high | |
| 30Weak | Peter J Mariani Chief Financial Officer buy | $19k 20,000 shares | +5% | - | |
| 30Weak | Peter J Mariani Chief Financial Officer buy | $28k 31,363 shares | +9% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 19, 2025 | MARIANI PETER J Officer | 10,548 0.02% of outstanding | $11k | Aug 19, 2025 | none |
Transactions
The newest 50 of 60 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Phillip P. Chan Chief Executive Officer | POpen-market purchase Common Stock | +3,774 | $6.00 | $23k | 100,996 | 27 d ago |
| Sep 15, 2026 | Alan D. Sobel director | POpen-market purchase Common Stock | +1,900 | $6.12 | $12k | 9,287 | 27 d ago |
| Sep 14, 2026 | Vincent Capponi President and COO | POpen-market purchase Common Stock | +1,800 | $6.07 | $11k | 40,114 | 27 d ago |
| Sep 14, 2026 | Vincent Capponi President and COO | POpen-market purchase Common Stock | +273 | $5.90 | $1,611 | 40,387 | 27 d ago |
| Sep 15, 2026 | Alan D. Sobel director | POpen-market purchase Common Stock | +500 | $6.05 | $3,025 | 9,787 | 27 d ago |
| Sep 15, 2026 | Alan D. Sobel director | POpen-market purchase Common Stock | +100 | $6.01 | $601 | 9,887 | 27 d ago |
| Sep 4, 2026 | Phillip P. Chan Chief Executive Officer | POpen-market purchase Common Stock | +200,000 | $0.35 | $70k | 1,944,432 | 34 d ago |
| Jun 15, 2026 | Peter J Mariani Chief Financial Officer | POpen-market purchase Common Stock | +100,000 | $0.44 | $44k | 638,113 | Jun 16, 2026 |
| Jun 12, 2026 | Phillip P. Chan Chief Executive Officer | POpen-market purchase Common Stock | +251,136 | $0.40 | $100k | 1,734,099 | Jun 15, 2026 |
| Jun 15, 2026 | Phillip P. Chan Chief Executive Officer | POpen-market purchase Common Stock | +10,333 | $0.43 | $4,443 | 1,744,432 | Jun 15, 2026 |
| Nov 18, 2025 | Phillip P. Chan Chief Executive Officer | AGrant or award Common Stock | +100,000 | $0.64 | $64k | 1,482,963 | Nov 20, 2025 |
| Aug 8, 2025 | Peter J Mariani Chief Financial Officer | AGrant or award Common Stock | +71,500 | $0.00 | $0 | 538,113 | Aug 8, 2025 |
| Aug 8, 2025 | Efthymios Deliargyris Chief Medical Officer | AGrant or award Common Stock | +70,000 | $0.00 | $0 | 473,025 | Aug 8, 2025 |
| Aug 8, 2025 | Vincent Capponi President and COO | AGrant or award Common Stock | +89,100 | $0.00 | $0 | 766,268 | Aug 8, 2025 |
| Aug 8, 2025 | Phillip P. Chan Chief Executive Officer | AGrant or award Common Stock | +105,600 | $0.00 | $0 | 1,382,963 | Aug 8, 2025 |
| Aug 8, 2025 | Phillip P. Chan Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +136,400 | $0.00 | $0 | 136,400 | Aug 8, 2025 |
| Aug 8, 2025 | Michael G. Bator director | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Aug 8, 2025 |
| Aug 8, 2025 | Efthymios Deliargyris Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +95,000 | $0.00 | $0 | 95,000 | Aug 8, 2025 |
| Aug 8, 2025 | Jiny Kim director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Aug 8, 2025 |
| Aug 8, 2025 | Peter J Mariani Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Aug 8, 2025 |
| Aug 8, 2025 | Edward Raymond Jones director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Aug 8, 2025 |
| Aug 8, 2025 | Vincent Capponi President and COO | AGrant or award Stock Option (Right to Buy)derivative | +111,100 | $0.00 | $0 | 111,100 | Aug 8, 2025 |
| Aug 8, 2025 | Alan D. Sobel director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Aug 8, 2025 |
| Feb 24, 2025 | Michael G. Bator director | OOut-of-the-money exercise Common Stock | +10,000 | $1.13 | $11k | 151,273 | Mar 4, 2025 |
| Feb 24, 2025 | Michael G. Bator director | OOut-of-the-money exercise Series A Right Warrants (right to buy)derivative | -15,879 | $1.13 | $18k | 0 | Mar 4, 2025 |
| Feb 24, 2025 | Peter J Mariani Chief Financial Officer | OOut-of-the-money exercise Common Stock | +32,625 | $1.13 | $37k | 466,613 | Feb 26, 2025 |
| Feb 24, 2025 | Vincent Capponi President and COO | OOut-of-the-money exercise Common Stock | +12,000 | $1.13 | $14k | 677,168 | Feb 26, 2025 |
| Feb 24, 2025 | Phillip P. Chan Chief Executive Officer | OOut-of-the-money exercise Common Stock | +34,168 | $1.13 | $39k | 1,277,363 | Feb 26, 2025 |
| Feb 24, 2025 | Alan D. Sobel director | OOut-of-the-money exercise Common Stock | +21,950 | $1.13 | $25k | 145,757 | Feb 26, 2025 |
| Feb 24, 2025 | Peter J Mariani Chief Financial Officer | OOut-of-the-money exercise Series A Right Warrants (right to buy)derivative | -32,625 | $1.13 | $37k | 0 | Feb 26, 2025 |
| Feb 24, 2025 | Vincent Capponi President and COO | OOut-of-the-money exercise Series A Right Warrants (right to buy)derivative | -12,000 | $1.13 | $14k | 0 | Feb 26, 2025 |
| Feb 24, 2025 | Phillip P. Chan Chief Executive Officer | OOut-of-the-money exercise Series A Right Warrants (right to buy)derivative | -34,168 | $1.13 | $39k | 0 | Feb 26, 2025 |
| Feb 24, 2025 | Alan D. Sobel director | OOut-of-the-money exercise Series A Right Warrants (right to buy)derivative | -21,950 | $1.13 | $25k | 0 | Feb 26, 2025 |
| Jan 17, 2025 | Michael G. Bator director | XIn-the-money exercise Common Stock | +15,879 | $1.00 | $16k | 141,273 | Jan 22, 2025 |
| Jan 17, 2025 | Vincent Capponi President and COO | XIn-the-money exercise Common Stock | +31,760 | $1.00 | $32k | 665,168 | Jan 22, 2025 |
| Jan 17, 2025 | Phillip P. Chan Chief Executive Officer | XIn-the-money exercise Common Stock | +90,832 | $1.00 | $91k | 1,243,195 | Jan 22, 2025 |
| Jan 17, 2025 | Peter J Mariani Chief Financial Officer | XIn-the-money exercise Common Stock | +32,625 | $1.00 | $33k | 433,988 | Jan 22, 2025 |
| Jan 17, 2025 | Efthymios Deliargyris Chief Medical Officer | XIn-the-money exercise Common Stock | +16,233 | $1.00 | $16k | 403,025 | Jan 22, 2025 |
| Jan 17, 2025 | Alan D. Sobel director | XIn-the-money exercise Common Stock | +21,950 | $1.00 | $22k | 123,807 | Jan 22, 2025 |
| Jan 17, 2025 | Michael G. Bator director | XIn-the-money exercise Subscription Rights (right to buy)derivative | -15,879 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Vincent Capponi President and COO | XIn-the-money exercise Subscription Rights (right to buy)derivative | -31,760 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Phillip P. Chan Chief Executive Officer | XIn-the-money exercise Subscription Rights (right to buy)derivative | -90,832 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Peter J Mariani Chief Financial Officer | XIn-the-money exercise Subscription Rights (right to buy)derivative | -32,625 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Efthymios Deliargyris Chief Medical Officer | XIn-the-money exercise Subscription Rights (right to buy)derivative | -16,233 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Michael G. Bator director | JOther Series A Right Warrantsderivative | +15,879 | - | - | 15,879 | Jan 22, 2025 |
| Jan 17, 2025 | Vincent Capponi President and COO | JOther Series A Right Warrantsderivative | +31,760 | - | - | 31,760 | Jan 22, 2025 |
| Jan 17, 2025 | Phillip P. Chan Chief Executive Officer | JOther Series A Right Warrantsderivative | +90,832 | - | - | 90,832 | Jan 22, 2025 |
| Jan 17, 2025 | Efthymios Deliargyris Chief Medical Officer | JOther Series A Right Warrantsderivative | +16,233 | - | - | 16,233 | Jan 22, 2025 |
| Jan 17, 2025 | Alan D. Sobel director | XIn-the-money exercise Subscription Rights (right to buy)derivative | -21,950 | $0.00 | $0 | 0 | Jan 22, 2025 |
| Jan 17, 2025 | Peter J Mariani Chief Financial Officer | JOther Series A Right Warrantsderivative | +32,625 | - | - | 32,625 | Jan 22, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Michael G. Batordirector
- Vincent CapponiPresident and COO
- Phillip P. ChanChief Executive Officer
- Efthymios DeliargyrisChief Medical Officer
- Edward Raymond Jonesdirector
- Jiny Kimdirector
- Peter J MarianiChief Financial Officer
- Alan D. Sobeldirector
Questions about CTSO
Answered from the filings on this page, as of the latest one.
Are insiders buying CTSO?
As of Sep 16, 2026, SEC Form 4 filings show 4 open-market buys worth $120k by 3 insiders and 0 open-market sells worth $0 by 0 insiders at Cytosorbents Corp in the last 90 days, net +$120k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade CTSO on the open market?
Vincent Capponi (President and COO) bought $13k of CTSO on Sep 14, 2026 and filed the Form 4 on Sep 16, 2026. InsiderTell scored 38 (weak), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Cytosorbents Corp?
8 people have filed a Form 4 at Cytosorbents Corp, among them Michael G. Bator (director), Vincent Capponi (President and COO), Phillip P. Chan (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.